A Multiple-Dose Study of LY3502970 in Healthy Participants

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 5, 2021

Primary Completion Date

February 10, 2022

Study Completion Date

February 10, 2022

Conditions

Healthy

Interventions

DRUG

LY3502970

Administered Orally.

Trial Locations (1)

Lilly Centre for Clinical Pharmacology, Singapore

All Listed Sponsors

lead

Eli Lilly and Company

INDUSTRY

NCT05110794 - A Multiple-Dose Study of LY3502970 in Healthy Participants | Biotech Hunter | Biotech Hunter